The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer

Thomas PowlesDepartment of Medical Oncology, St Bartholomew’s Hospital, London, United KingdomCorrespondence[email protected]

Siobhan McFaulDepartment of Medical Oncology, St Bartholomew’s Hospital, London, United Kingdom

Justin StebbingDepartment of Medical Oncology, St Bartholomew’s Hospital, London, United Kingdom

Peter WilsonDepartment of Medical Oncology, St Bartholomew’s Hospital, London, United Kingdom

Tim OliverDepartment of Medical Oncology, St Bartholomew’s Hospital, London, United Kingdom

Naomi TranterDepartment of Medical Oncology, St Bartholomew’s Hospital, London, United Kingdom

Jonathan ShamashDepartment of Medical Oncology, St Bartholomew’s Hospital, London, United Kingdom

show all

Pages 35-39 | Published online: 30 Sep 2008

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

BlayJYLe CesneARay-CoquardI2007Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma GroupJ Clin Oncol2511071317369574
PubMed Web of Science ®Google Scholar
De MulderPHWeissbachLJakseG1996Gemcitabine: a phase II study in patients with advanced renal cancerCancer Chemother Pharmacol3749158599874
PubMed Web of Science ®Google Scholar
DreicerR2006Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effectsClin Genitourin Cancer5Suppl 1S192317239280
PubMed Web of Science ®Google Scholar
EscudierBEisenTStadlerWMTARGET Study Group2007Sorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med3561253417215530
PubMed Web of Science ®Google Scholar
GeorgeCMVogelzangNJRiniBI2002A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinomaAnn Oncol131162011863091
PubMed Web of Science ®Google Scholar
KishJAWolfMCrawfordED1994Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group StudyCancer7491698039119
PubMed Web of Science ®Google Scholar
MotzerRJBacikJSchwartzLH2004Prognostic factors for survival in previously treated patients with metastatic renal cell carcinomaJ Clin Oncol224546314752067
PubMed Web of Science ®Google Scholar
MotzerRJHutsonTETomczakP2007Sunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med3561152417215529
PubMed Web of Science ®Google Scholar
MotzerRJMichaelsonMDRedmanBG2006Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaJ Clin Oncol24162416330672
PubMed Web of Science ®Google Scholar
PatardJJPouesselDBensalahK2008Targeted therapy in renal cell carcinomaWorld J Urol261354018265991
PubMed Web of Science ®Google Scholar
PortaCZimatoreMImarisioI2004Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II studyCancer1002132815139055
PubMed Web of Science ®Google Scholar
RiniBIVogelzangNJDumasMC2000Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancerJ Clin Oncol1824192610856102
PubMed Web of Science ®Google Scholar
RyanCWVogelzangNJStadlerWM2002A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinomaCancer942602912173327
PubMed Web of Science ®Google Scholar
ShamashJSteeleJPWilsonP2003IPM chemotherapy in cytokine refractory renal cell cancerBr J Cancer8815162112771915
PubMed Web of Science ®Google Scholar
StadlerWMHuoDGeorgeC2003Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancerJ Urol1701141514501711
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date